Patent: 9,187,496
✉ Email this page to a colleague
Summary for Patent: 9,187,496
| Title: | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| Abstract: | Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. ##STR00001## |
| Inventor(s): | Dousson; Cyril B. (Canet, FR), Dukhan; David (Saint Gely du Fesc, FR), Parsy; Christophe Claude (Jacou, FR), Pierra; Claire (Montarnaud, FR), Alexandre; Francois-Rene (Montpellier, FR), Brandt; Guillaume (Montpellier, FR), Da Costa; Daniel (Saint Jean de Vedas, FR), Rahali; Houcine (Saint Laurent des Arbres, FR), Paparin; Jean-Laurent (Vendemian, FR), Derock; Michel (Grabels, FR), Convard; Thierry (Sathonay-Camp, FR), Surleraux; Dominique (Wauthier-Braine, BE) |
| Assignee: | Idenix Pharmaceuticals LLC (Cambridge, MA) |
| Application Number: | 13/675,787 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,187,496
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche Inc. | PEGASYS COPEGUS COMBINATION PACK | peginterferon alfa-2a and ribavirin | 125083 | 06/04/2004 | ⤷ Try a Trial | 2029-12-18 | |
| Schering Corporation A Subsidiary Of Merck & Co., Inc. | PEGINTRON/ REBETOL COMBO PACK | peginterferon alfa-2b and ribavirin | 125196 | 06/13/2008 | ⤷ Try a Trial | 2029-12-18 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
